BCTXLBriaCell Therapeutics Corp. Warrant expiring 2031

WARRANTNasdaq (XNAS)·USD

Identity

Enriched 2026-08-14 20:47

Market cap: —
Shares outstanding (class): 2,793,296
Shares outstanding (weighted): —
SIC: 2834 PHARMACEUTICAL PREPARATIONS
Employees: 4
Location: WEST VANCOUVER, A1
Homepage: https://www.briacell.com
Description: BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.

Market cap and share counts drift.

as of 2026-03-31

No reported positions at this date.

Positions are reached through OpenFIGI-resolved ISINs. A security with no resolved ISIN cannot be found this way even if funds do hold it.

master.security_identifier

Not classified.

5,771 of 13,106 active securities have an assignment so far. This one is still in the queue.

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.